NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT05092451 2026-03-18Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer CenterPhase 1/2 Recruiting80 enrolled
NCT06026319 2026-03-16CD79b-19 CAR T Cells in Non-Hodgkin LymphomaMassachusetts General HospitalPhase 1 Recruiting24 enrolled
NCT03277729 2026-01-05A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasFred Hutchinson Cancer CenterPhase 1/2 Active not recruiting53 enrolled 11 charts